Content about Lilly

May 9, 2013

Sears Holdings has appointed Jeff Balagna as EVP and chief information officer, the Kmart parent company said Thursday.

HOFFMAN ESTATES, Ill. — Sears Holdings has appointed Jeff Balagna as EVP and chief information officer, the Kmart parent company said Thursday.

Balagna was previously chief information officer for drug maker Eli Lilly and will be responsible for Sears Holdings' technology and infrastructure initiatives in its support centers and in-store.

May 2, 2013

Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

BI and Lilly created the website sglt.com to inform users about the role of sodium glucose co-transporters. The program also includes a video, Glucose Perspectives, in the form of a sketch animation by the United Kingdom's Royal Society for the Encouragement of Arts, Manufactures and Commerce.

March 25, 2013

Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said.

RIDGEFIELD, Conn. — Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said Monday.

BI and Lilly announced the submission of a regulatory application to the Food and Drug Administration for empagliflozin. The drug belongs to a new drug class known as SGLT2 inhibitors, which work by removing excess glucose through the urine by blocking its reabsorption in the kidneys. The companies are testing the drug in a late-stage clinical trial for which they plan to enroll 14,500 patients.

January 29, 2013

Eli Lilly and Company reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

INDIANAPOLIS — Eli Lilly and Company on Tuesday reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

November 2, 2012

Eli Lilly is spending $140 million to expand its insulin manufacturing plant in Indianapolis, the drug maker said.

INDIANAPOLIS – Eli Lilly is spending $140 million to expand its insulin manufacturing plant in Indianapolis, the drug maker said.

Lilly said it would expand the plant by 80,000 sq. ft., saying it represented one of the most significant investments in its U.S. manufacturing operations in the past decade. Construction is expected to start immediately, with completion planned for March 2014.

September 17, 2012

The University of Colorado Health Partners, The Little Clinic and King Soopers have announced an affiliation that will provide consumers with more options to improve their health through improved healthcare services, access to professionals in a variety of fields, such as nutrition and wellness programs.

DENVER — The University of Colorado Health Partners, The Little Clinic and King Soopers have announced an affiliation that will provide consumers with more options to improve their health through improved healthcare services, access to professionals in a variety of fields, such as nutrition and wellness programs.
 

September 4, 2012

Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

INDIANPOLIS — Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

The Lilly Glucagon mobile app is an interactive tool designed to teach caregivers how to use severe hypoglycemia treatment Glucagon (1-mg) for injection through simulated practice, thus helping caregivers better understand Glucagon's role in diabetes management. The Lilly Glucagon mobile app includes:

  • Information about severe hypoglycemia and Glucagon;

March 8, 2012

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately.

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately. At the end of January, the Food and Drug Administration approved Bydureon (exenatide), a once-weekly version of the drug Byetta, which was originally developed by Alkermes and subsequently developed further under an alliance between Amylin Pharmaceuticals and Eli Lilly that the two companies formed in 2002. In November 2011, however, Amylin and Lilly terminated their alliance in the wake of an announced diabetes drug partnership between Lilly and Boehringer Ingelheim.

November 8, 2011

Eli Lilly and Amylin Pharmaceuticals are ending their diabetes-drug alliance, the two companies said Tuesday.

SAN DIEGO — Eli Lilly and Amylin Pharmaceuticals are ending their diabetes-drug alliance, the two companies said Tuesday.

Indianapolis-based Lilly and San Diego-based Amylin said they would terminate their alliance concerning exenatide, the active ingredient in the injected diabetes drug Byetta and its long-acting version, Bydureon, currently under investigation.

October 24, 2011

The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

The FDA announced the approval of generic olanzapine tablets and olanzapine orally disintegrating tablets, respectively generic versions of Lilly's Zyprexa and Zyprexa Zydus. Dr. Reddy's Labs and Teva Pharmaceuticals USA will manufacture olanzapine tablets, while Dr. Reddy's, Apotex and Par Pharmaceuticals will manufacture the orally disintegrating version.

June 28, 2011

Eli Lilly will invest funds into its existing biotechnology capabilities to further research and development of multispecific therapeutics.

WASHINGTON — Eli Lilly will invest funds into its existing biotechnology capabilities to further research and development of multispecific therapeutics.

May 31, 2011

An Eli Lilly executive was elected to Chiquita's board of directors at the company's annual shareholders meeting.

CINCINNATI — An Eli Lilly executive was elected to Chiquita's board of directors at the company's annual shareholders meeting.

Chiquita said that Jeffrey Simmons, who serves as Lilly SVP and president of the drug maker's animal health division, Elanco Animal Health, brings more than 20 years of management experience to his new role on the audit committee and the food innovation, safety and technology committee.

July 20, 2010

Drug maker Eli Lilly has finished its acquisition of a company developing a pancreatic disorder...